Development of a transdermal sumatriptan formulation with iontophoresis
{{output}}
Objective: A transdermal iontophoretic formulation for sumatriptan was approved by the U.S. FDA in 2013 for patients who cannot take oral medications. However, it was withdrawn in 2020 due to skin burns and scarring associated wi... ...
